Baggstrom相关文献与解析，生知库 | 链接生命科学的每一步

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

抗 VEGF/PDGFR 药物 vorolanib 联合免疫检查点抑制剂治疗晚期实体瘤患者的 1b 期试验

Bagegni, Nusayba A; Park, Haeseong; Kraft, Katlyn; O-Toole, Maura; Gao, Feng; Waqar, Saiama N; Ratner, Lee; Morgensztern, Daniel; Devarakonda, Siddhartha; Amin, Manik; Baggstrom, Maria Q; Liang, Chris; Selvaggi, Giovanni; Wang-Gillam, Andrea

VEGF

A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations

一项针对携带 TSC1、TSC2、NF1、NF2 或 STK11 突变的晚期实体恶性肿瘤患者的依维莫司 II 期研究

期刊:Journal of Thoracic Disease

影响因子:1.9

doi:10.21037/jtd-21-195

Devarakonda, Siddhartha; Pellini, Bruna; Verghese, Luke; Park, Haeseong; Morgensztern, Daniel; Govindan, Ramaswamy; Suresh, Rama; Oppelt, Peter; Baggstrom, Maria Q; Wu, Ningying; Waqar, Saiama N

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

厄洛替尼联合贝伐珠单抗与厄洛替尼单药治疗晚期EGFR突变型非小细胞肺癌患者无进展生存期的比较：一项II期随机临床试验

期刊:Jama Oncology

影响因子:20.1

doi:10.1001/jamaoncol.2019.1847

Stinchcombe, Thomas E; Jänne, Pasi A; Wang, Xiaofei; Bertino, Erin M; Weiss, Jared; Bazhenova, Lyudmila; Gu, Lin; Lau, Christie; Paweletz, Cloud; Jaslowski, Anthony; Gerstner, Gregory J; Baggstrom, Maria Q; Graziano, Stephen; Bearden, James 3rd; Vokes, Everett E

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

Seribantumab联合厄洛替尼治疗EGFR野生型非小细胞肺癌患者的随机II期试验

期刊:Oncologist

影响因子:4.2

doi:10.1634/theoncologist.2018-0695

Sequist, Lecia V; Gray, Jhanelle Elaine; Harb, Wael A; Lopez-Chavez, Ariel; Doebele, Robert C; Modiano, Manuel R; Jackman, David Michael; Baggstrom, Maria Quintos; Atmaca, Akin; Felip, Enriqueta; Provencio, Mariano; Cobo, Manuel; Adiwijaya, Bambang; Kuesters, Geoffrey; Kamoun, Walid S; Andreas, Karen; Pipas, J Marc; Santillana, Sergio; Cho, Byoung Chul; Park, Keunchil; Shepherd, Frances A

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

一项 III 期随机、安慰剂对照、双盲试验，评估塞来昔布联合标准化疗治疗环氧合酶-2 过表达的晚期非小细胞肺癌的疗效：CALGB 30801（Alliance）

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.2016.71.3743

Edelman, Martin J; Wang, Xiaofei; Hodgson, Lydia; Cheney, Richard T; Baggstrom, Maria Q; Thomas, Sachdev P; Gajra, Ajeet; Bertino, Erin; Reckamp, Karen L; Molina, Julian; Schiller, Joan H; Mitchell-Richards, Kisha; Friedman, Paula N; Ritter, Jon; Milne, Ginger; Hahn, Olwen M; Stinchcombe, Thomas E; Vokes, Everett E

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance)

在晚期 IIIB/IV 期非小细胞肺癌患者接受初始铂类联合化疗后，使用舒尼替尼进行维持治疗：一项随机、双盲、安慰剂对照的 III 期研究 - CALGB 30607 (Alliance)

期刊:Journal of Thoracic Oncology

影响因子:20.8

doi:10.1016/j.jtho.2017.01.022

Baggstrom, Maria Q; Socinski, Mark A; Wang, Xiaofei F; Gu, Lin; Stinchcombe, Thomas E; Edelman, Martin J; Baker, Sherman Jr; Feliciano, Josephine; Novotny, Paul; Hahn, Olwen; Crawford, Jeffrey A; Vokes, Everett E

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

T2N0M0期非小细胞肺癌患者的辅助化疗

期刊:Journal of Thoracic Oncology

影响因子:20.8

doi:10.1016/j.jtho.2016.05.022

Morgensztern, Daniel; Du, Lingling; Waqar, Saiama N; Patel, Aalok; Samson, Pamela; Devarakonda, Siddhartha; Gao, Feng; Robinson, Cliff G; Bradley, Jeffrey; Baggstrom, Maria; Masood, Ashiq; Govindan, Ramaswamy; Puri, Varun

Racialized economic segregation and disparities in non-small cell lung cancer care and outcomes

种族化的经济隔离以及非小细胞肺癌治疗和预后方面的差异

Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer

种族化的经济隔离与小细胞肺癌的治疗和预后

Investing in Women Trainees: Building a Women in Medicine Group at an Academic Institution

投资于女性学员：在学术机构建立女性医学生团队

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

抗 VEGF/PDGFR 药物 vorolanib 联合免疫检查点抑制剂治疗晚期实体瘤患者的 1b 期试验

A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations

一项针对携带 TSC1、TSC2、NF1、NF2 或 STK11 突变的晚期实体恶性肿瘤患者的依维莫司 II 期研究

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

厄洛替尼联合贝伐珠单抗与厄洛替尼单药治疗晚期EGFR突变型非小细胞肺癌患者无进展生存期的比较：一项II期随机临床试验

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

Seribantumab联合厄洛替尼治疗EGFR野生型非小细胞肺癌患者的随机II期试验

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

一项 III 期随机、安慰剂对照、双盲试验，评估塞来昔布联合标准化疗治疗环氧合酶-2 过表达的晚期非小细胞肺癌的疗效：CALGB 30801（Alliance）

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance)

在晚期 IIIB/IV 期非小细胞肺癌患者接受初始铂类联合化疗后，使用舒尼替尼进行维持治疗：一项随机、双盲、安慰剂对照的 III 期研究 - CALGB 30607 (Alliance)

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

T2N0M0期非小细胞肺癌患者的辅助化疗